The story of Zhejiang Huahai Pharmaceuticals Co. Ltd.’s contaminated valsartan API is continuing to unfold, with European authorities criticizing a summertime quick fix to the firm’s API manufacturing process and the US FDA putting Huahai’s API plant on import alert – and using the occasion to warn the broader pharmaceutical industry against letting dangerous impurities get into other drug products.
One longtime leader in API manufacturing called on the industry to alert its young workers what can go wrong, recalling...





